Pro- and Anti-inflammatory Cytokines in Latent Autoimmune Diabetes in Adults, Type 1 and Type 2 Diabetes Patients: Action LADA 4

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2011 Feb 25

PMID 21347621

Citations 38

Authors

M N Pham

M I Hawa

C Pfleger

M Roden

G Schernthaner

P Pozzilli

R Buzzetti

W A Scherbaum

W Scherbaum

J Seissler

H Kolb

S Hunter

R D G Leslie

N C Schloot

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Systemic pro- and anti-inflammatory cytokines are associated with both type 1 and type 2 diabetes, while their role in latent autoimmune diabetes in adults (LADA) is unclear. Therefore, we compared cytokine concentrations in patients with LADA, type 1 or type 2 diabetes and healthy individuals to test the hypothesis that differences of cytokine concentrations between all groups are attributable to diabetes type and BMI.

Methods: The pro-inflammatory cytokines IL-6 and TNF-α, and the anti-inflammatory cytokines IL-1 receptor antagonist (IL-1RA) and IL-10 were measured in 90 participants with type 1 diabetes, 61 with LADA, 465 with type 2 diabetes and 41 control participants using multiple regression models adjusted for BMI, sex, age, blood pressure and diabetes duration.

Results: Patients with type 2 diabetes had higher concentrations of systemic IL-1RA, IL-6 and TNF-α cytokines than patients with either LADA or type 1 diabetes (p < 0.0001 for all differences). Cytokine concentrations in controls were lower than those in all diabetes types (p < 0.04). Increased BMI was positively associated with higher systemic cytokine concentrations in all diabetes types (p < 0.0001). Despite the association of cytokines with anthropometric data, differences between diabetes forms persisted also after adjusting analysis for the confounders BMI, age, sex, disease duration and blood pressure (p < 0.04).

Conclusions/interpretation: Although body mass associates positively with pro- and anti-inflammatory cytokine levels, patients with type 2 diabetes have higher cytokine levels independent of the prevailing BMI. LADA and type 1 diabetes could not be distinguished by systemic cytokines.

Citing Articles

Update on Biomarkers of Chronic Inflammatory Processes Underlying Diabetic Neuropathy.

Stoian A, Muntean C, Baba D, Manea A, Denes L, Simon-Szabo Z Int J Mol Sci. 2024; 25(19).

PMID: 39408723 PMC: 11476795. DOI: 10.3390/ijms251910395.

Latent autoimmune diabetes in adults in China.

Qiu J, Xiao Z, Zhang Z, Luo S, Zhou Z Front Immunol. 2022; 13:977413.

PMID: 36090989 PMC: 9454334. DOI: 10.3389/fimmu.2022.977413.

Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy.

Hu J, Zhang R, Zou H, Xie L, Zhou Z, Xiao Y Front Endocrinol (Lausanne). 2022; 13:917169.

PMID: 35937817 PMC: 9350734. DOI: 10.3389/fendo.2022.917169.

Latent Autoimmune Diabetes in Adults and Metabolic Syndrome-A Mini Review.

Pan N, Yang S, Niu X Front Endocrinol (Lausanne). 2022; 13:913373.

PMID: 35837301 PMC: 9273866. DOI: 10.3389/fendo.2022.913373.

Innate immunity in latent autoimmune diabetes in adults.

Huang J, Pearson J, Wong F, Wen L, Zhou Z Diabetes Metab Res Rev. 2021; 38(1):e3480.

PMID: 34156143 PMC: 8813511. DOI: 10.1002/dmrr.3480.

References

Hartkamp A, Geenen R, Bijl M, Kruize A, Godaert G, Derksen R . Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2004; 63(10):1335-7. PMC: 1754758. DOI: 10.1136/ard.2003.011825. View

Leslie R, Kolb H, Schloot N, Buzzetti R, Mauricio D, de Leiva A . Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev. 2008; 24(7):511-9. DOI: 10.1002/dmrr.877. View

Troseid M, Seljeflot I, Hjerkinn E, Arnesen H . Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care. 2008; 32(3):486-92. PMC: 2646034. DOI: 10.2337/dc08-1710. View

Pfleger C, Meierhoff G, Kolb H, Schloot N . Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J Autoimmun. 2009; 34(2):127-35. DOI: 10.1016/j.jaut.2009.08.004. View

Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M . Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes. 1997; 46(9):1526-31. DOI: 10.2337/diab.46.9.1526. View

Ortis F, Naamane N, Flamez D, Ladriere L, Moore F, Cunha D . Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes. 2009; 59(2):358-74. PMC: 2809955. DOI: 10.2337/db09-1159. View

Larsen C, Faulenbach M, Vaag A, Volund A, Ehses J, Seifert B . Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007; 356(15):1517-26. DOI: 10.1056/NEJMoa065213. View

Tisch R, McDevitt H . Insulin-dependent diabetes mellitus. Cell. 1996; 85(3):291-7. DOI: 10.1016/s0092-8674(00)81106-x. View

Herder C, Brunner E, Rathmann W, Strassburger K, Tabak A, Schloot N . Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2008; 32(3):421-3. PMC: 2646020. DOI: 10.2337/dc08-1161. View

10.

Shoelson S, Herrero L, Naaz A . Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132(6):2169-80. DOI: 10.1053/j.gastro.2007.03.059. View

11.

Vozarova B, Weyer C, Hanson K, Tataranni P, Bogardus C, Pratley R . Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001; 9(7):414-7. DOI: 10.1038/oby.2001.54. View

12.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

13.

Pickup J, Crook M . Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia. 1998; 41(10):1241-8. DOI: 10.1007/s001250051058. View

14.

Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L . Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003; 26(2):452-7. DOI: 10.2337/diacare.26.2.452. View

15.

Basu S, Larsson A, Vessby J, Vessby B, Berne C . Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care. 2005; 28(6):1371-5. DOI: 10.2337/diacare.28.6.1371. View

16.

Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R . Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol. 2008; 128(1):57-65. DOI: 10.1016/j.clim.2008.03.458. View

17.

Juge-Aubry C, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C . Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 2003; 52(5):1104-10. DOI: 10.2337/diabetes.52.5.1104. View

18.

Campbell I, Oxbrow L, Harrison L . Reduction in insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimmun. 1991; 4(2):249-62. DOI: 10.1016/0896-8411(91)90022-5. View

19.

Nicoletti F, Zaccone P, Di Marco R, Magro G, Grasso S, Stivala F . Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats. Diabetes. 1998; 47(1):32-8. DOI: 10.2337/diab.47.1.32. View

20.

Carstensen M, Herder C, Kivimaki M, Jokela M, Roden M, Shipley M . Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes. 2010; 59(5):1222-7. PMC: 2857902. DOI: 10.2337/db09-1199. View